Heat transfer problems for the production of hydrogen from geothermal energy

Autor: Sigurvinsson, J., Mansilla, C., Arnason, B., Bontemps, A., Maréchal, A., Sigfusson, T.I., Werkoff, F.

Publikováno v: In Energy Conversion and Management 2006 47(20):3543-3551

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL

Autor: Duquette, P, Despault, L, Knobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Lapierre, Y, Greenstein, J, Mishra, B, Delillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::a2f1b7542488dd044ee9c1603bb77653
https://ora.ox.ac.uk/objects/uuid:205c2be5-9239-483c-ac75-c71b99307e11

Suppression of experimental allergic encepbalomyelitis in guinea-pigs with poly-L-Iysine.

Autor: Ewachelmicka-Szorc¹, Arnason, B. G. W.¹

Publikováno v: Clinical & Experimental Immunology. Dec1975, Vol. 22 Issue 3, p539-545. 7p.

250 mu g or 500 mu g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Autor: O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H., Jeffery, D., Kappos, L., Boateng, F., Filippov, V., Groth, M., Knappertz, V., Kraus, C., Sandbrink, R., Pohl, C., BogumilAbramsky O, T., Achiron, A, Agius, M, Aichner, F, Altenkirch, H, Amato, Mp, Anten, B, Arbizu, T, Ash, P, Ballario, C, Bashir, K, Baum, K, Baumhackl, U, Beaver, G, Belova, A, Berger, J, Berger, T, Berlit, P, Beuche, W, Bhan, V, Bigley, K, Bissay, V, Blake, C, Bö, L, Boyko, A, Brochet, B, Brown, M, Callegaro, D, Carra, A, Carroll, W, Cascione, M, Christie, S, Clanet, M, Clavelou, P, Clementino, Vi, Confavreux, C, Cooper, J, Cross, A, Csanyi, A, Czlonkowska, A, D'Hooghe, M, Damier, P, Debouverie, M, Defer, G, Demina, T, Deri, N, Diem, R, Dressel, A, Dubois, B, Dunne, P, Duquette, P, Durelli, L, Edan, G, Elias, S, Elovaara, I, Esfahani, F, Evtushenko, S, Fabijan, Th, Fernández, O, Ferreira, Ml, Fink, A, Flechter, S, Ford, C, Francesconi, C, Freedman, M, Fryze, W, Gabbai, A, Gács, G, Gallo, Paolo, Gazda, S, Gerloff, C, Glyman, S, Goodman, A, Gottesman, M, Grand'Maison, F, Guarnaccia, J, Gutierrez, A, Haas, J, Hansen, Hj, Hardiman, O, Heard, R, Heidenreich, F, Herbert, J, Herminia Scola, R, Hodgkinson, S, Hoffmann, F, Holub, R, Huddlestone, J, Hughes, B, Hughes, M, Hunter, S, Hurwitz, B, Izquierdo, G, Jacobasch, E, Jacques, F, Jakab, G, Jongen, P, Karageorgiou, C, Karni, A, Kasper, L, Kaufman, M, Keidel, M, Khatri, B, Kiefer, R, Kirzinger, S, Kita, M, Komoly, S, Kotov, S, Kozubski, W, Kumlien, E, Kwiecinski, H, Labouge, P, Laganke, C, Lapierre, Y, Lebrun Frenay, C, Leist, T, Leon, Sa, Luetic, G, Lynch, S, Lynch, T, Malkova, N, Maltezou, M, Markowitz, C, Martin, C, Mattle, H, Mattson, D, Metra, M, Meyding Lamadé, U, Milo, R, Milonas, I, Miller, A, Miller, T, Minagar, A, Mitchell, G, Moreau, T, Mosberg, R, Murphy, R, Nehrych, T, Nikl, J, Odinak, M, Oschmann, P, Owen King, J, Pagani, L, Pereira Damasceno, B, Podemski, R, Pöhlau, D, Pozzilli, C, Rammohan, K, Reunanen, M, Rice, G, Richardson, P, Rivera, V, Rizvi, S, Rogozhyn, V, Rolak, L, Rosenkranz, T, Rotta, R, Sanders, E, Sater, R, Satgur Gupta, A, Schwartz, R, Sedal, L, Sega Jazbec, S, Selchen, D, Selmaj, K, Sheremata, W, Shvets, T, Silver, D, Simsarian, J, Skoromets, A, Smiroldo, J, Sokolova, L, Solovyova, Y, Sommer, N, Spirin, N, Stangel, M, Stark, E, Steinbrecher, A, Stemper, B, Stolyarov, I, Strasser Fuchs, S, Sweeney, B, Tettenborn, B, Thrower, B, Tilbery, Cp, Traboulsee, A, Trojano, M, Tubridy, N, Tyor, W, Valikovics, A, Vermersch, P, Vollmer, T, Voloshyna, N, Vrech, C, Wajgt, A, Weller, B, Wendt, J, Yakhno, N, Yeung, M, Zavalishin, I.

BACKGROUND: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 microg or 500 microg interferon beta-1b with glatiramer acetate for treating relapsing-remitting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a37623d2c38a7327df763e9df25424
http://hdl.handle.net/11577/2486283

Kan akut nyreinsufficiens øge effekten af warfarin?

Autor: Hanne Madsen, Arnason, B., Matthisson, J.

Publikováno v: Madsen, H, Arnason, B & Matthisson, J 2009, ' Kan akut nyreinsufficiens øge effekten af warfarin? ', Ugeskrift for læger, bind 171, nr. 1012 .
University of Southern Denmark

Udgivelsesdato: 2009

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::68397845f85fac4e4f69506b82b22afa
https://portal.findresearcher.sdu.dk/da/publications/c597b2e0-2415-11de-ae62-000ea68e967b